The clinical and epidemiologic features of respiratory syncytial virus (RSV) infections suggest that RSVspecific antibody may sometimes contribute to the disease process. Recently, it has been demonstrated that virus-specific antibody can enhance RSV infection of macrophagelike cells in vitro. We evaluated the possibility that antibody might also enhance RSV stimulation of the bronchoactive mediator of inflammation leukotriene C-4 (LTC4) in a macrophagelike cell line, U937. The addition of RSV led to little increase in LTC4 production, but addition of RSV plus anti-RSV antibody increased production to a level similar to that achieved with calcium ionophore, a known stimulator of LTC4 production. The antibody-enhanced increase in LTC4 production occurred rapidly (within 15 min), peaked at 60 min, and achieved levels 1.5-to 3.0-fold above that for cells or cells plus virus. RSV plus anti-RSV antibodies in the form of polyclonal serum, monoclonal antibodies, or F(ab')2 fragments and parainfluenza virus types 1 and 3 plus their respective antibodies all increased LTC4 levels over that for the virus alone. These results demonstrate that antibody plus the corresponding virus or protein can increase leukotriene production. This phenomenon could contribute to diseases, such as RSV bronchiolitis, that appear to be caused by an interaction between the virus (or antigen) and host immunity.
Respiratory syncytial virus (RSV) is the single most important cause of severe lower respiratory tract disease in infants and young children. The most distinctive clinical feature of RSV disease in infants and young children is bronchiolitis, a syndrome in which the child develops bronchospasm similar to that seen with asthma (26) . The fact that the peak age for RSV bronchiolitis, 2 to 6 months of age, is also a time when the infant has persistent maternal anti-RSV antibodies suggests that these antibodies may contribute to the disease process (19) . Several studies have also demonstrated that high-titer maternally acquired neutralizing antibody sometimes protects against serious disease (17, 18, 30) . Antibody-mediated enhancement (AME) of infection is one mechanism by which antibody could contribute to protection in some infants and disease in others (29) . Two groups have now demonstrated that AME of RSV infection occurs in vitro in macrophagelike cells (16, 24) . In those studies, the yield of infectious virus was low and led us to postulate that AME might contribute to disease by mechanisms other than lytic infection of cells.
One possibility is that the virus or virus plus antibody, when it interacts with host cells, stimulates the release of mediators of inflammation or cytokines that in turn contribute to the disease process. Some have suggested that RSVspecific immunoglobulin E (IgE) is present in patients with RSV bronchiolitis and might cause disease through an immediate hypersensitivity-type reaction (7, (44) (45) (46) . One group noted that RSV antigen-antibody complexes stimulate the production of thromboxane in neutrophils, and thromboxane can cause smooth-muscle contraction (14) . Recently, the concentration of leukotriene C4 (LTC4) in respiratory secretions has been associated with RSV bronchiolitis (40, 41) . Leukotrienes are products of arachidonic acid metabolism via the 5-lipoxygenase pathway, are potent mediators of * Corresponding author. allergic and inflammatory responses (9, 27, 33) , and can cause constriction of the small airways of the lung (47) . Insoluble immune complexes with IgE and aggregates of IgG have been shown to stimulate LTC4 in macrophages, eosinophils, and basophils (15, (36) (37) (38) 48) . We felt that leukotrienes were particularly promising as potential contributors to RSV bronchiolitis and chose to evaluate this possibility by examining the effect of RSV plus RSV-specific antibody on LTC4 production in vitro in a macrophagelike cell line. Our findings suggest that virus plus virus-specific antibody increases the production of leukotrienes, a process that may contribute to RSV disease.
(This work was presented in part at the 8th International Congress of Virology, Berlin, Federal Republic of Germany, August 1990, and at the Annual Meeting of the American Society for Virology, Salt Lake City, Utah, July 1990.) MATERIALS AND METHODS U937 cells. The U937 cell line was chosen for these studies because it has macrophagelike characteristics and worked well in studies of AME of RSV infection in our laboratory. This hematopoietic cell line is derived from a patient with generalized histiocytic lymphoma (39) . Like most monocytes, U937 cells show strong esterase activity that is inhibited by NaF. More than 30% of the cells were positive for CD4 and Fc surface receptors on the basis of flow cytometric analysis. U937 cells as well as monocytes produce leukotrienes (12) .
The U937 cells were grown in RPMI 1640 supplemented with 10% fetal calf serum, 100 ,ug of streptomycin per ml, 100 U of penicillin per ml, and 1% glutamine at 37°C and 5% CO2. Just before leukotriene stimulation studies, cells were harvested, pelleted at 1,200 x g for 10 (3, 4) . The endpoint dilution was calculated by the Reed-Muench method and was considered to contain one 50% tissue culture infective dose of virus (TCID50).
The titer of antigen in the respective virus preparation was determined by previously described time-resolved fluoroimmunoassays (20) . For parainfluenza virus types 1 and 3, the hemagglutination titer was determined by using guinea pig erythrocytes (21) .
Antibodies. The RSV-positive serum pool consisted of eight adult serum specimens that were positive for IgG and negative for IgA and IgM RSV antibodies. The RSV-negative serum was from an infant less than 1 year old and was negative for RSV IgG, IgA, and IgM antibodies by antibody capture EIAs (13) . The human anti-parainfluenza virus type 1 and 3 sera were convalescent-phase specimens from children with parainfluenza virus type 1 and 3 infections, respectively. The seven RSV monoclonal antibodies (MAbs) used in this study have been previously described (2, 5, 6 ) and include three anti-F protein (131-2a, 133-lh, and 143-6c), three anti-G protein (130-6d, 130-Sf, and 232-if), and one anti-N protein (130-12h) monoclone.
The neutralizing antibody titer for the positive human serum specimens was determined by a previously described tissue culture EIA (4). Virus-specific IgG, Fc, and F(ab')2 titers were determined by reacting serial dilutions of antibody against virus-infected and uninfected tissue culture material adsorbed to 96-well microtiter plates (Costar, Cambridge, Mass.), washing the plates, adding peroxidase-conjugated anti-human IgG, anti-human F(ab')2, or anti-human Fc antibodies (Pierce, Rockford, Ill.), washing the plates, adding substrate (tetramethylbenzidine), and reading A450. A reaction was considered positive if the absorbance reading for infected material was more than three standard deviations above the mean of uninfected material.
RSV IgG and F(ab')2 preparations. The RSV IgG was purified from the RSV-positive human serum pool described above on a DEAE-sephacel column (32) . Part production as a proxy for overall leukotriene production. LTC4 was extracted from the cell supernatant by a modification of a previously published procedure (34) . Briefly, at the end of the stimulation period, the cells and supernatant were put on ice for 15 min and centrifuged for 10 min at 1, 200 x g at 4°C, and the supernatant was decanted into clean siliconized glass tubes. Two milliliters of methanol-acetonitrile (50%, vol/vol) was added to deproteinize the sample. Next, the sample was centrifuged at 1,500 x g for 10 min at 4°C, the pellet was discarded, and the supernatant was collected and either lyophilized or vacuum evaporated to dryness. The dried samples were stored at -70°C under argon until tested for LTC4 by a competition RIA (LTC4 radioimmunoassay kit; New England Nuclear, Boston, Mass.). To perform the assay, the samples were resuspended in 0.1 ml of the assay buffer supplied as part of the kit. The RIA was performed as recommended by the manufacturer and as described by Aeringhaus et al. (1) . LTC4 standards and LTC4-negative control were included in each run. The negative control was not adsorbed with charcoal. A standard curve constructed for each run was used to estimate the concentration of LTC-in the sample. The LTC4 RIA gave consistent results, with a 95% confidence interval for five replicates of less than or equal to + 15% of the mean value for a given experiment. A 50% increase in LTC4 levels was .2 and usually >3 standard deviations above the mean and was considered a significant increase. The anti-LTC4 antibody cross-reacts with LTD4 and LTE4, and thus the RIA also detects these two leukotrienes but with less sensitivity than LTC4.
Reverse-phase HPLC analysis. Supernatants from RSVonly and RSV-plus-IgG stimulations were concentrated and partially purified by using C18-Sep-Pak columns (Waters Associates, Milford, Mass.). The columns were equilibrated with methanol and deionized water before the samples were loaded. After the samples were loaded, the column was washed with deionized water containing methanol (60% water and 40% methanol) and eluted with 100% methanol. The eluates were evaporated to dryness under vacuum and then resuspended in 100 ,ul of 30% methanol in deionized water for high-performance liquid chromatography (HPLC) separation. The 
RESULTS
Characteristics of LTC4 production. An increase in LTC4 levels occurred rapidly after the addition of 10 nM calcium ionophore A23187. An increase in LTC4 levels over that after the addition of media was detected within 5 min and peaked at about 15 min (Fig. 1) . In contrast, RSV alone gave minimal increase in LTC4 levels above that for media, and the RSV-positive serum pool gave levels of LTC4 similar to that with RSV alone and with a similar time course (data not shown). The RSV-positive serum pool plus RSV markedly increased LTC4 levels with a time course similar to that for calcium ionophore (Fig. 1) . This increase was noted within 15 min of stimulation and peaked at about 60 min. We chose to use 60-min stimulation times in the studies described below.
The status of the cells at the time of stimulation proved important for antibody enhancement of LTC4 production. The To demonstrate that the increase in LTC4 levels was specific for the antigen-antibody interaction, we tested a variety of control reactants as summarized in Fig. 3 with calcium ionophore. All the anti-RSV MAbs mixed with RSV significantly increased LTC4 over that for RSV alone (data not shown). These included MAbs against the F, G, and N proteins and of subclasses IgGl, IgG2a, and IgG2b.
This increase occurred over dilutions of 10-2 to 10-6 and to (n = 3). Antibody-enhanced LTC4 production occurred at a lower range of antibody dilutions for parainfluenza virus types 1 and 3 (10-1 to 10-3) than for RSV (10-2 to 10-6) ( Fig.   2B and C) . This difference occurred despite similar neutralizing titers of the respective antibodies ( kindly provided by S. Hildreth and P. Paradiso, Praxis Biologics, Rochester, N.Y. (42, 43) , were tested with and without antibody. The individual proteins stimulated levels of LTC4 higher than that achieved with virus alone (1.89-fold for F and 3.56-fold for G protein) (Fig. 4) . We felt that the increased levels of LTC4 produced with the individual proteins might have occurred because of antibody that coeluted off the affinity column with the proteins. To test this hypothesis, we evaluated LTC4 levels with the affinitypurified proteins after adsorption with protein G Sepharose (Pharmacia LKB Biotechnology, Piscataway, N.J.) and F and G proteins partially purified from cell lysate by column chromatography. The affinity-purified proteins adsorbed with protein G did not give increased levels of LTC4, but the addition of antibody to the adsorbed proteins did significantly increase the levels of LTC4 produced (Fig. 4) . Similarly, the column-purified proteins did not give increased levels of LTC4. The two peaks from the column that contained F and G proteins by EIA gave levels of LTC4 0.75-and 0.67-fold above that for RSV alone, while the addition of RSV-positive serum pool at a 1:1,000 dilution increased LTC4 levels for the two peaks to 1.91-and 2.17-fold above that for RSV alone. The specificity of antibody-enhanced LTC4 is further supported by the fact that a G protein MAb plus the affinity-purified F protein gave no enhancement (0.88-fold compared with that for F alone), while an F protein MAb plus the affinity-purified F protein gave enhancement of 1.65-fold compared with that for F alone.
Fc receptors and LTC4 production. To investigate the possibility that antibody enhancement of LTC4 production occurred by way of the Fc receptor in a fashion similar to AME of infection, we looked at the ability of purified anti-RSV (IgG from the serum pool) and F(ab')2 fragments to enhance LTC4 production. The F(ab')2 preparation was free of whole IgG by polyacrylamide gel electrophoresis and Coomassie brilliant blue staining; a heavy band was seen at 110 kDa [consistent with F(ab')2], and no band was seen at 160 kDa (consistent with IgG). The F(ab')2 fragment had a titer of 1:128 against RSV with an anti-F(ab')2 detector and a titer <1:2 with the anti-Fc detector. In comparison, purified IgG had a titer of 1:512 with both the anti-F(ab')2 and anti-Fc detectors. The F(ab')2 enhanced LTC4 production to a level similar to that for purified anti-RSV IgG (Fig. 5 and Table 3 ). In contrast, the purified IgG gave RSV AME, while the F(ab')2 gave no AME (Fig. 5 ). Preincubating cells with anti-Fc receptor 1 and anti-Fc receptor 3 antibodies did not affect LTC4 levels produced by RSV plus antibody, while anti-Fc receptor 2 antibodies at dilutions of (10-2 to 10-4) did appear to decrease levels of LTC4 from about 2-fold to 1.2-fold over that for virus alone.
LTC4 production in human peripheral blood monocytes. In initial studies to determine whether antibody enhancement of leukotriene production might contribute to RSV disease, we tested the ability of antibody to increase LTC4 production by RSV in peripheral blood monocytes from five volunteers (Table 4 ). The level of antibody enhancement of LTC4 for peripheral blood monocytes from four donors was similar to that seen with U937 cells, 2.4-to 3.4-fold above that for virus alone. With cells from one volunteer, the levels were increased only by 1.2-fold with the addition of specific antibody.
DISCUSSION
This study demonstrates that virus-specific antibody can enhance in vitro stimulation of LTC4 production by RSV and parainfluenza virus types 1 and 3. In U937 cells, the addition of virus was associated with LTC4 levels similar to that with cells alone, but the addition of virus plus virus-specific antibody was associated with a 1.5-to 3.0-fold increase in LTC4 levels. This level of stimulation was similar to that achieved with a known stimulator of leukotrienes, calcium ionophore A23187 (37) . Conversely, serum lacking the virus specific antibody or a MAb against a different virus and a variety of other controls did not increase leukotriene levels above that produced when medium was added to cells. Thus, the increase in levels of LTC4 appeared to require the corresponding virus-specific antibody. We also demonstrated antibody enhancement of LTC4 levels with RSV F and G proteins plus their corresponding specific antibodies.
The potential range of antigens plus the specificity of the antibody-antigen interaction make this phenomenon an intriguing potential mechanism for a number of disease processes that involve both viruses or foreign antigens and host immunity. RSV (11) . The data, from one experiment, are representative of three experiments. Note that LTC4 levels were significantly (>1.5-fold) increased with the addition of IgG or F(ab')2 to RSV, but levels of RSV-positive cells were increased only after addition of IgG but not after addition of F(ab')2.
but do not ensure protection from disease (17, 18, 30) . If host immunity fails to prevent spread of virus to the lower respiratory tract, then antibody plus virus or antibody plus viral proteins (presumably in the form of complexes) would be present in the bronchioles, where their reaction with macrophages or other cells could release leukotrienes and cause bronchospasm. Leukotrienes have also been proposed as mediators of some of the symptoms associated with allergic rhinitis and asthma (7, 23) . Recently, a leukotriene inhibitor has been shown to sometimes decrease symptoms of allergic rhinitis (23) . Foreign antigens plus the host's specific antibodies increasing cellular release of leukotrienes or other mediators of inflammation might explain the contribution of host immunity to these disease processes. Studies to explore the potential link between antibody enhancement of leukotriene production and diseases such as RSV bronchiolitis are in progress.
We chose to measure LTC4 as a proxy for leukotriene production because an RIA was available commercially. LTC4 is produced from LTA4 and is metabolized to LTD4, which is then metabolized to LTE4. LTC4, LTD4, and LTE4 have bronchospastic activity, while LTB4, which is metabolized by another pathway, does not (26, 31 It was surprising to find that the mechanism for antibody enhancement of leukotriene production was apparently distinct from that for AME. Digesting IgG to F(ab')2, as expected, did not eliminate the ability of the antibody to react with RSV but did eliminate its ability to enhance RSV infection in the U937 cells. In contrast, it did not eliminate its ability to enhance RSV stimulation of leukotriene production. It is possible that undigested RSV IgG, IgA, or IgM was present in the F(ab')2 preparation. However, we did not detect IgG by gel electrophoresis in the F(ab')2 preparation or RSV-specific IgA or IgM by EIA (13) in the original preparation. In blocking experiments, on the other hand, anti-Fc receptor 2 antibodies did decrease levels of LTC4 associated with addition of antibody to RSV. This could have occurred by blocking the Fc receptor directly or possibly by attachment at the Fc receptor affecting another receptor. The apparent disparate results with F(ab')2 and blocking experiments make the role of Fc receptors in this phenomenon unclear but do suggest that their role, if any, is distinct from that for AME of infection. We have not yet identified a promising alternate receptor. It is known that arachidonic acid, the precursor of leukotrienes, is stored in the cell membrane as a phospholipid ester that is removed and made available to the cell through receptor-mediated, calcium-dependent activation of specific lipases (8, 12, 28) . The receptors on the cell surface that are activated by unopsonized zymosan, calcium ionophore, and bacterial lipopolysaccharide are known to be capable of stimulating leukotriene production but are not known to bind antibody-antigen complexes (22) . Previous studies have demonstrated that LTC4 or LTB4 levels produced by eosinophils, basophils, or macrophages can be increased by adding aggregates of IgG, IgA, and IgE; IgG or IgE reacted against antigen-coated beads; or large immune complexes of IgE and albumin (15, 35, 38, 48) . It has been suggested but not clearly shown that this occurs through immune complexes binding to the Fc receptor. Our data suggest that soluble antigen-IgG antibody complexes can also stimulate leukotriene production and that if this occurs through the Fc receptor, it does so independently of the Fc fragment of the antibody. Further study is required to clarify this issue.
This study demonstrates that increases in leukotrienes by the interaction of antibody with antigen are not limited to insoluble immune complexes of IgE antibodies but can occur with the type of IgG-mediated immune complexes that might form in the lungs or other organs. Their presence in the vicinity of resident monocytes could in turn cause the release of leukotrienes and contribute to the disease process in that organ, for example, bronchospasm in RSV bronchiolitis or asthma.
